Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | PDE4A | P27815 | 11/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 11/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 11/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Methylxanthine SCHEMBL17748264 | 0.94 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6233166 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL27395394 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL1892011 | 0.90 | ADORA2B (0.92) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11661797 | 0.88 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL21381249 | 0.88 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL27396492 | 0.87 | ADORA2A (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL380135 | 0.87 | ADORA2A (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7217322 | 0.86 | ADORA2A (0.97) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10181082 | 0.85 | PDE4A (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3217985-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| WO-2016075285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2016-05-19 | — | — | WO | claimed |
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-6117878-A | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors | UNIVERSITY OF VIRGINIA (US) | 2000-09-12 | — | — | US | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| US-4980379-A | ENHANCING EFFICIENCY BY REDUCING ADENOSINE LEVELS | THE UNIVERSITY OF VIRGINIA (US) | 1990-12-25 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4436567-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | Astrocyte Pharmaceuticals, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-0267607-B1 | 8-ARYLXANTHINES | MARION MERRELL DOW INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4980379-A | ENHANCING EFFICIENCY BY REDUCING ADENOSINE LEVELS | THE UNIVERSITY OF VIRGINIA (US) | 1990-12-25 | — | — | US | disclosed |
| US-4975432-A | IMPROVED BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-04 | — | — | US | disclosed |
| EP-0267607-A1 | 8-Arylxanthines | MARION MERRELL DOW INC. (US) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | ADORA2B 48/4885ADORA2A 23/4885PDE4A 282/4885 |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ADORA2A, ADORA3, ADORA1 | ADORA2B 4/4885ADORA2A 1/4885PDE4A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.